Introduction
Emerging evidence suggests that chronic or recurrent prostate inflammation may initiate and promote prostate cancer development (De Marzo et al., 2007; Sutcliffe and Platz, 2007; Haverkamp et al., 2008; Bardia et al., 2009 ). However, rational chemoprevention or treatment of prostate cancer with anti-inflammatory drugs has not been fully exploited, in part due to the lack of understanding of the molecular and cellular mechanisms by which inflammation influences prostate carcinogenesis (Bardia et al., 2009) .
The pleiotropic cytokine interleukin-6 (IL-6) is produced by various inflammatory cells in the tissue microenvironment through activation of the inflammatory transcriptional nuclear factor, nuclear factor-kB (Grivennikov and Karin, 2008) . As an established major mediator of inflammation, IL-6 has been suggested to facilitate prostate cancer progression to androgenindependent disease and potentially to promote bone metastasis (Corcoran and Costello, 2003; Paule et al., 2007; Ishiguro et al., 2009; Ara and Declerck, 2010; Santer et al., 2010) . The elevated level of serum IL-6 or the persistent activation of the IL-6 signaling components of signal transducer and activator of transcription 3 (STAT3) in prostate carcinomas has been correlated with the shortened survival of patients with prostate cancer (Nakashima et al., 2000; Tam et al., 2007) . These studies have suggested the significance of IL-6 in the malignant progression of prostate cancer. However, whether IL-6 has a causative role in facilitating the progression from pre-malignant states to overt malignancy remains unclear.
In this study, we demonstrate that IL-6 can induce tumorigenic conversion of the immortal but of the nontumorigenic prostate epithelium, a process accompanied by an epithelial-to-mesenchymal transition (EMT) leading to an invasive phenotype, through activation of STAT3. Interestingly, we find that IL-6 exposure not only stimulates the IL-6 autocrine loop but also leads to activation of insulin-like type I growth factor receptor (IGF-IR) signaling through autocrine secretion of IGF-IR ligands IGF-I and IGF-II and upregulation of IGF-IR expression. Moreover, we find that activation of STAT3 is critical in establishing the autocrine network of IL-6 and the IGF axis. To our knowledge, this is the first report linking the pro-inflammatory cytokine IL-6 to the endocrine IGF axis in facilitating prostate malignancy and the overt progression to an invasive phenotype.
Results

IL-6 induces EMT of benign prostate epithelial cells
To understand the role of IL-6 in prostate tumorigenesis, we treated the SV40T-immortalized benign nontumorigenic prostate epithelial cell line P69 with IL-6 at a concentration of 10, 20, 50 or 100 ng/ml. After 24 h exposure, P69 cells exhibited a spindle-like depolarized fibroblast-like morphology at all concentrations of IL-6 ( Figure 1a and data not shown). This morphology and related properties persisted for at least five passages in culture after withdraw of IL-6 (Supplementary Figure  S1 ). Immunofluorescence staining and western blot analyses demonstrated that the morphological changes were associated with gain of the molecular features of EMT (Zeisberg and Neilson, 2009) , such as loss of E-cadherin and induction of Vimentin (Figures 1a and b ).
Concomitantly, real-time reverse transcriptase-PCR (RT-PCR) analyses showed that changes in gene expression patterns were consistent with EMT, including repression of E-cadherin and induction of Vimentin, N-cadherin and Snail in P69 cells treated with IL-6 compared with control-untreated cells (Figure 1c ).
We further determined that IL-6 induced similar changes in the expression of E-cadherin and/or Vimentin in immortalized non-tumorigenic BPH-1 cells and in primary prostate epithelial cells (Supplementary Figure S2 ). These observations suggest that the effects of IL-6 on P69 cells represent a general effect of IL-6 on prostate epithelial cells, and not a cell line-specific effect.
Increased cell migration is one of the characteristics of cells undergoing EMT. Accordingly, we evaluated the migratory potential of P69 cells in the presence or absence of IL-6 in wounding assays. Cell monolayers were incised and then exposed to serum-free medium supplemented with IL-6 or serum. Wound closure was measured at early time points, such as 12 h, which were representative of migration rather than proliferation. In the presence of IL-6, P69 cells demonstrated markedly increased migration than did serum controls (Figure 1d ).
IL-6 induces EMT through activation of STAT3 and IGF-IR signaling Interleukin-6 signals through a specific IL-6 receptor and a promiscuous transmembrane signal transducer, gp130, to activate the JAK2/STAT3 pathway (Corcoran and Costello, 2003) . As shown in Figure 2a , exposure to IL-6 induced phosphorylation of STAT3 and associated loss of E-cadherin in P69 cells. In the presence of the STAT3 inhibitor AG490, IL-6 showed no effect or a minimal effect on E-cadherin expression. These data suggested a key role of STAT3 activation in IL-6 induction of EMT.
Inflammatory cytokines have been shown to act through cell-surface growth factor receptor pathways (Soon et al., 1999; Corcoran and Costello, 2003; Al-Shanti et al., 2008; Colomiere et al., 2009) . IL-6 has been shown to induce EMT in ovarian carcinomas through cross-activation of STAT3 and the epidermal growth factor receptor, which is frequently overexpressed in ovarian cancers (Colomiere et al., 2009) . As IGF-IR has an important role in tumorigenesis and in the neoplastic growth of prostate Werner and Bruchim, 2009) , we are thus motivated to investigate whether IGF-IR has a role in the induction of EMT by IL-6. As shown by western blotting analyses ( Figure 2b ) and immunofluorescence staining (Figure 2c ), blocking IGF-IR with a specific antibody IMC-A12 either abrogated or markedly reduced the effect of IL-6 on E-cadherin and Vimentin expression in P69 and BPH-1 cells, whereas treatment of these cells with IMC-A12 alone had no effect or a minimal effect IL-6 promotes prostate tumorigenesis through IGF-IR A Rojas et al on E-cadherin or Vimentin expression. These results suggested that IGF-IR signaling has a critical role in IL-6 induction of EMT.
IL-6 induction of EMT is associated with the gain of malignant phenotypes
Epithelial-to-mesenchymal transition has been recently proposed to be a central process for cancer development, progression and metastasis (Thiery, 2002; Thiery et al., 2009) . Thus, undergoing EMT may signify the acquisition of a malignant phenotype, which in prostate epithelial cells can be distinguished from a nonmalignant phenotype by the morphological structures formed in three-dimensional Matrigel cultures (Zhang et al., 2009) . We examined the morphological characteristics of P69 and BPH-1 cells in Matrigel with or without IL-6. Consistent with other studies (Zhang et al., 2009) , in the absence of IL-6, P69 and BPH-1 cells form small, smooth, well-formed acini after 15 days of culture ( Figures 3a and b , top right panels). Immunostaining and confocal microscopy of a series of sections through an acinus (Z-stack section) showed that these acini were multicellular, highly organized and polarized with a notable clear empty lumen (Figures 3a and b , middle and bottom right panels). These acini structures are very similar to those formed by the normal prostate glandular epithelium embedded in a matrix of stromal cells. In addition, akin to normal prostate epithelia cells (Long et al., 2005) , E-cadherin was polarized on the outside edge of the acinus and Vimentin was absent.
In the presence of IL-6, P69 or BPH-1 cells did not organize into smooth acini; instead, cells grew out of the spheroids, sometimes with protrusion into the surrounding Matrigel (Figures 3a and b , top left panels). Immunostaining showed the loss of E-cadherin and gain of Vimentin expression ( Figures 3a and b , middle and bottom left panels). These characteristics are very similar to those observed in the highly tumorigenic and progressed M12 prostate cell line (Zhang et al., 2009) . These data suggest that IL-6 enables non-tumorigenic prostate epithelial cells to gain characteristics similar to those of tumorigenic prostate epithelial cells in association with induction of EMT.
Activation of IGF-IR is also critical for IL-6 induction of malignant transformation
The induction of tumor-like spheres formed by benign P69 and BPH-1 cells after exposure to IL-6 suggests that IL-6 may have the ability to induce or facilitate cellular transformation. To test this hypothesis, we first evaluated the mitogenic effect of IL-6 on benign prostate epithelial cells. As shown in Figure 4a , IL-6 stimulates proliferation of P69 and BPH-1 cells in serumfree media. Consistent with the above observations, the IGF-IR-blocking antibody IMC-A12 abrogates the mitogenic effect of IL-6.
We next evaluated the capacity of benign epithelial cells, in the presence or absence of IL-6, to form anchorage-independent colonies in soft agar, a property associated with a malignant cell phenotype. In the absence of IL-6, P69 cells plated in soft agar resulted in very few colonies and the number and size of these colonies remained unchanged over time (Figures 4b and c ), verifying their untransformed phenotype. Those putative colonies of P69 in the absence of IL-6 were attributed to cells that were clumped at the time of seeding. In the presence of IL-6, P69 cells gained the capacity to form sizable and large numbers of colonies (Figures 4b and c) . These data indicate that IL-6 may To further investigate the potential role of IL-6 in prostate malignancy, we performed a luciferase reporter assay using the promoter derived from the cancer progression elevated gene-3 (PEG-3) (Su et al., 1997 (Su et al., , 2005 . Previous studies have shown that PEG-3 promoter activation is cancer specific and displayed elevated activity in tumorigenic cancer cell lines in comparison with non-tumorigenic benign cells (Su et al., 2005) . As shown in Figure 4d , in the presence of IL-6, PEG-3 promoter activity was markedly increased in both P69 and BPH-1 cells (Po0.001). However, the PEG-3 promoter activity was inhibited by AG490 to block STAT3 activation or by IMC-A12 to block IGF-IR signaling. These data suggest that IL-6 has the potential to facilitate tumorigenesis of benign non-tumorigenic prostate epithelial cells and that both STAT3 and IGF-IR have critical roles in such an event.
IL-6 facilitates in vivo tumorigenesis and metastatic progression A more stringent assay for the malignant phenotype is the ability to form a tumor in vivo. Thus, we overexpressed IL-6 in P69 and BPH-1 cells (designated as P69 IL-6 and BPH-1 IL-6 ) and implanted these cells subcutaneously into immune-deficient athymic nude mice. Consistent with previous reports, parental P69 and BPH-1 cells (with the empty vector) did not form tumors in nude mice in a 3-month post-implantation analysis period (Figures 5a and b) . In contrast, tumors IL-6 promotes prostate tumorigenesis through IGF-IR A Rojas et al were formed within 10 days of inoculation in all animals implanted with P69 IL-6 or BPH-1 IL-6 cells (Figure 5a ). We further addressed the metastatic potential of tumors formed by P69 IL-6 or BPH-1 IL-6 cells by removing primary tumors from animals through survival surgery at 6 weeks after inoculation. Metastasis was observed in the lymph nodes of all tumor-bearing animals in a 2-week post-surgery follow-up, as confirmed by SV40Tantigen (SV40Tag) immunostaining of these tissues (Figure 5c ). Vimentin was abundantly expressed in both primary and metastasized tumors (Figure 5c ), consisting of the in vitro observed feature associated with EMT. These data confirm that IL-6 can not only induce tumorigenic conversion but also promote tumor progression to metastasis.
Activation of STAT3 is critical for the autocrine loop of IL-6 and activation of IGF-IR To investigate the mechanisms by which IL-6 may act through IGF-IR signaling, we first examined the activation status of IGF-IR in P69 cells with IL-6 treatment. Without exogenous ligands IGF-I or IGF-II, IGF-IR was phosphorylated only at a basal level in serum-free media to maintain the viability of cells (Figure 6a ; Damon et al., 2001) . In the presence of IL-6, phosphorylation of IGF-IR was markedly increased without addition of exogenous IGF-I or IGF-II; moreover, the phosphorylation was inhibited by the STAT3 inhibitor, AG490 (Figure 6a ). Semi-quantitative real-time RT-PCR demonstrated that IL-6 upregulated the expression of IGF-I and IGF-II (Figures 6b and 6c) , as well as that of IGF-IR (Figure 6d) . Similarly, this effect of IL-6 was inhibited by the STAT3 inhibitor, AG490. Moreover, IL-6 also stimulated P69 cells to produce autocrine IL-6 and to upregulate the expression of IL-6 signaling components, gp130 and IL-6R, through STAT3 activation (Figures 6e-g) . Similar effects of IL-6 were also observed in BPH-1 cells (Supplementary Figure S3) . These results demonstrate that paracrine IL-6 can stimulate autocrine activation of IGF-IR and engage an autocrine IL-6 loop and that activation of STAT3 is critical in maintaining these autocrine activities.
Transcriptional reprogramming of benign prostate epithelial cells by IL-6
To identify the potential genetic changes underlying IL-6-mediated tumorigenesis and associated EMT, we examined the transcriptional reprogramming of P69 cells exposed to IL-6 using 44 K whole human genome expression oligonucleotide microarray analyses. We identified an array of genes that were upregulated and a cohort of 176 genes that were significantly upregulated (q 2 o0.05) in P69 cells after IL-6 treatment (Figure 7a and data not shown). These include panels of known genes encoding inflammation-related cytokines and chemokines, extracellular matrix components, transcription factors and tumorigenesis-associated factors ( Supplementary Table S1 ). The significant upregulation of IL-6-and EMT-associated hallmarkers, such as N-cadherin, Vimentin and Snail, as exhibited by microarray analyses is consistent with the data as described above throughout our experiments. We also validated the upregulated expression of the two well-studied carcinogenesis-associated genes, K-Ras and Lipocalin 2 (LCN2), by quantitative RT-PCR (Figure 7b ). Mutations or overexpression of the oncogene K-Ras have been associated with tumorigenesis (Rosen et al., 2006; Karnoub and Weinberg, 2008; Traynor et al., 2008) . Human IL-6 was stably expressed in benign P69 and BPH-1cells (designated as P69 IL-6 and BPH-1 IL-6 , respectively). Overall, 2 Â 10 6 cells per mouse of P69 IL-6 or BPH-1 IL-6 , or parental P69 or BPH-1 cells were s.c. implanted into groups of nude mice. (a) Tumor incidence in animals that were implanted with P69 IL-6 or BPH-1 IL-6 stable genetically modified cells or parental P69 or BPH-1 cells. Data show that all animals that were implanted with P69 IL-6 or BPH-1 IL-6 cells developed tumors within 10 days, whereas no tumor was formed in animals that were implanted with parental P69 or BPH-1 cells. (b) Growth and volume of tumors (mean ± s.e.) formed by P69 IL-6 and BPH-1 IL-6 cells. (c) IHC staining of SV40T-Ag and Vimentin showing that tumors formed by P69 IL-6 cells metastasized to the lymph node and that Vimentin was abundantly expressed in these tumors. Scale bar, 100 mm.
blocking IGF-IR signaling with the antibody IMC-A12 or blocking STAT3 activation with AG490 significantly inhibited IL-6-induced upregulation of K-Ras and LCN2 (Figure 7b ). These data suggest that IL-6 induces a reprogramming of cellular transcriptional activity and upregulates the expression of a spectrum of genes that are critical for tumor initiation and progression. The data also suggest that STAT3 and IGF-IR activation has a significant role in IL-6-induced reprogramming of cellular transcription.
Discussion
Interleukin-6 has been shown to transactivate the androgen receptor in prostate cancer cells through the STAT3 pathway to facilitate androgen independence (Corcoran and Costello, 2003; Ishiguro et al., 2009) . In this study, for the first time, we demonstrate that IL-6 has a causal role in de novo prostate tumorigenesis and malignant progression to invasiveness of otherwise non-tumorigenic benign prostate epithelial cells. More interestingly, we demonstrate that IL-6 facilitates tumorigenesis and progression through a novel pathway, the autocrine activation of IGF-IR. We demonstrate that IL-6 and the IGF axis form a potent autocrine network through activation of STAT3. This is the first report demonstration of the network of inflammatory cytokine IL-6 and the autocrine IGF axis in promoting prostate tumorigenesis. In this study, we demonstrate that IL-6 induces an EMT in association with the gain of malignancy of benign prostate epithelial cells. IL-6 has also been shown to facilitate breast tumor growth and metastasis through induction of EMT (Sullivan et al., 2009) . Although the pathways of EMT in epithelial cancers are not fully understood, activation of an EMT program has been proposed as the critical mechanism for the acquisition of invasiveness and metastasis (Kang and Massague, 2004) . Consistent with this concept, autocrine expression of IL-6 in benign P69 and BPH-1 cells resulted in not only transformation and in vivo tumor formation but also tumor progression to metastasis. Our findings are consistent with those in colitis-associated cancers, which showed that IL-6 was not only important for early tumor development but also critical for latestage tumor progression (Becker et al., 2004; Grivennikov et al., 2009) .
Interleukin-6 is also a result of obesity, which is associated with an increased risk of developing aggressive prostate cancer and mortality (Freedland and Platz, 2007) . The periprostatic adipose tissue has been shown to be a major source of IL-6 and indicated to facilitate the development of high-grade prostate cancer through IL-6 signaling (Finley et al., 2009) . Although the underlying biological mechanism is not fully understood, it has been speculated that the association of obesity with increasing prostate cancer aggressiveness may have resulted from endocrine derangements (O'Malley and Taneja, 2006; Irigaray et al., 2007) . Our data revealed that paracrine IL-6 in the prostate microenvironment, which resulted from inflammation or periprostatic adipose tissues, can instigate a vicious endocrine loop of IL-6 and thus maintain a sustained endocrine activation of the IGF-IR through persistent activation of STAT3. Our data have defined one of the mechanisms by which obesity may be associated with prostate endocrine derangement and prostate cancer progression to aggressiveness.
Interleukin-6 has been proposed as a target for treating androgen-independent prostate cancer. In this study, we demonstrate a critical role of IL-6 in prostate cancer development and a potential role in facilitating progression to metastasis. Thus, targeting the IL-6 signaling pathway may also be of particular interest in prostate cancer prevention and in the treatment or prevention of metastatic diseases. However, a clinical trial with an anti-IL-6 monoclonal antibody CNTO328 in prostate cancer patients with advanced diseases did not present adequate efficacy (Dorff et al., 2010) . The poor therapeutic outcome with the anti-IL-6 antibody may be in part due to the overriding vicious autocrine loop of IL-6, and possibly the IGF axis in malignant tumor cells as we have shown. Given the critical role of STAT3 in maintaining the autocrine IL-6 loop and in activating IGF-IR during prostate cancer tumorigenesis and malignant progression as we have presented in this study, targeting STAT3, potentially in combination with targeting IGF-IR, may be an alternative strategy to an anti-IL-6 antibody in perturbing IL-6 signaling for advanced prostate cancer treatment or for inflammation-associated prostate cancer prevention.
Materials and methods
Cell lines and culture
The generation and characterization of the benign nontumorigenic prostate epithelial cell line P69 has been described previously (Bae et al., 1994) . The benign human prostate epithelial cell line BPH-1 was obtained from the American Type Cell Culture (Manassas, VA, USA). Cells were maintained in RPMI 1460 media supplemented with 10% fetal bovine serum, 100 Units/ml penicillin and 100 mg/ml streptomycin. For IL-6 treatment, cells were cultured in serum-free media with IL-6 of indicated concentration with or without the presence of the IGF-IR-blocking antibody IMC-A12 (Burtrum et al., 2003; Rowinsky et al., 2007) for the period as indicated. The IMC-A12 antibody is IGF-IR specific and does not react with the insulin receptor (Rowinsky et al., 2007) . The Stat3 inhibitor AG490 (Cayman Chemical, Ann Arbor, MI, USA) was resuspended in dimethyl sulfoxide and a final concentration of 10 mM was used.
Proliferation assay
Cells were seeded in a 96-well plate at the density of 2500 cells/ well in serum-free media for 24 h before addition of 50 ng/ml IL-6 and/or the IMC-A12 antibody. Proliferation was quantified after 48 h by a colorimetric MTS tetrazolium (MTT) assay using the Cell Titer 96 AQueous kit (Promega, Madison, WI, USA) as described previously (Coe et al., 2007) . Eight replicates were performed for each experiment. 
IL-6 promotes prostate tumorigenesis through IGF-IR
A Rojas et al Three-dimensional Matrigel culture Three-dimensional cultures were prepared as described previously (Zhang et al., 2009) . In brief, cells (1 Â 10 6 ) were mixed with 1 ml undiluted Matrigel and seeded in a six-well culture dish. After polymerization at 37 1C for 1 h, the Matrigel/cell mixture was overlayed with the appropriate medium. The same batch of Matrigel was used throughout this study. The medium was replaced every 3 days. Cultures were grown for up to 15 days.
Immunofluorescence
For two-dimensional culture, cells were plated onto sterile round microscope slides in 24-well plates and grown to 70% confluence. After washing, cells were fixed with 4% paraformaldehyde for 30 min at 4 1C. After three washes, cells were blocked with 5% non-fat milk for 1 h at room temperature, followed by incubating with an anti-E-cadherin mouse monoclonal antibody (kindly provided by Dr William Carter at the Fred Hutchinson Cancer Research Center, Seattle, WA, USA) and/or an anti-Vimentin rabbit monoclonal antibody SP20 (Lab Vision Products, Fremont, CA, USA) overnight at 4 1C. After several washes, cells were incubated with Alexa Fluor 488-conjugated (Invitrogen, Carlsbad, CA, USA) or Alexa Fluor 594-conjugated (Invitrogen) secondary antibodies for 1 h. DAPI (5 mg/ml) was used to stain the nuclei. Slides were mounted using SlowFade (Invitrogen). For staining of the three-dimensional culture, a sample (B10 ml) of the Matrigel culture was spread on each well of a four-well chamber slide, air dried and fixed in 1:1 methanol/ acetone at 20 1C for 10 min. After washing with phosphatebuffered saline, the slides were incubated with the blocking solution, primary antibodies and fluorochrome-conjugated secondary reagents as described above. Slides were visualized under a Zeiss LSM 510 confocal microscope (Thornwood, NY, USA). Representative pictures were shown from experiments repeated at least twice with 20-50 morphological structures analyzed.
Western blots
Cells were lysed in cold lysis buffer (30 mM HEPES, 150 mM NaCl, 1.5 mM MgCl 2 , 1mM EGTA, 10% Triton X-100) containing protease and phosphatase inhibitor cocktail II (Sigma, St Louis, MO, USA). In all, 25 mg of clear cell lysates of each sample was resolved in a 10-14% SDS-PAGE gel and transferred to a nitrocellulose membrane. After blocking with 5% non-fat milk in TBST buffer (20 mM Tris-HCl, pH 7.5, containing 0.15 M NaCl, 0.5, 0.1% Tween 20), blots were incubated overnight at 4 1C with appropriate antibodies, followed by horseradish peroxidase-linked secondary antibodies (Cell Signaling, Danvers, MA, USA). Proteins were detected using enhanced chemiluminescence reagents (Amersham, Piscataway, NJ, USA). Antibodies specific to the following molecules were used: pSTAT3 (Cell Signaling), total STAT3 (Cell Signaling), E-cadherin (a gift from Dr William Carter, Fred Hutchinson Cancer Research Center), Vimentin (Lab Vision Products), phospho-IGF-IR (Biosource, Carlsbad, CA, USA), IGF-IR (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (glyceraldehyde 3-phosphate dehydrogenase, Cell Signaling).
Quantitative RT-PCR Total RNA was extracted using TRizol (Invitrogen). cDNA was synthesized using the SuperScript II kit (Invitrogen). A volume of 1 ml of cDNA was mixed with Power SYBR Green PCR MasterMix (Applied Biosystems, Carlsbad, CA, USA), and specific primers sets were added to a final concentration of 400 nM in 20 ml of reaction mixture. The reaction was run on an ABI9700 machine and data were analyzed using the Lightcycler software v3.5 (Roche Applied Science, Indianapolis, IN, USA). Each sample was assayed in triplicates. Target mRNA levels were normalized against GAPDH. The primers used are listed in Supplementary Table S2 .
Wound assay Cells were plated in six-well plates with complete RPMI 1460 medium and grown to confluence. After rinsing cells twice with phosphate-buffered saline, the cell layer was scratched with a 10-ml pipette tip and overlaid with serum-free RPMI 1460 in the presence or absence of 50 ng/ml IL-6. Wound width was measured at 0, 12 and 24 h after wounding.
Anchorage-independent growth
Anchorage-independent cell growth was assayed by the capacity of cells to form colonies in soft agar as described in detail elsewhere (Bae et al., 1994) . In brief, 1 Â 10 4 cells were plated on Petri dishes in 0.3% agar/media. The number and size of colonies were documented at indicated time points.
Plasmids, transfection and PEG-3 promoter luciferase reporter assay
The construction of PEG-3 promoter-Luciferase plasmid (pPEG3-Luc) and luciferase assay was described previously (Su et al., 2000 (Su et al., , 2001 (Su et al., , 2005 . Cells were transiently transfected with the pPEG3-Luc plasmid using Lipofectamine 2000 (Invitrogen). Luciferase assays were performed 48 h after transfection.
Isolation and overexpression of IL-6 cDNA of human IL-6 was amplified by PCR from P69 cells after exposure to IL-6. The following primers were used: (forward) 5 0 -TCTCGAGAGCCCAGCTATGAACTC-3 0 and (reverse) 5 0 -ATAGCGGCCGCTTACTACATTTGCCGAA GA-3 0 . After sequence confirmation, the cDNA of IL-6 was subcloned into the retroviral vector pBMN-IRES-GFP (Orbigen Inc., San Diego, CA, USA), which contains a cDNA for GFP (green fluorescent protein) as a reporter. The construct was transfected into the Ampho-Phoenix packaging cell line (Orbigen Inc.). Retroviral was produced according to the manufacture's protocol and used to transduce target cells. GFP-positive cells were isolated by flow cytometry sorting. The expression of IL-6 was confirmed by RT-PCR.
In vivo tumorigenicity and progression
All studies were conducted according to the regulation of the IACUC protocol. Overall, 2 Â 10 6 cells were injected subcutaneously into the right flanks of 5-to 6-week-old nude male mice (Harlan-Sprague-Dawley, Indianapolis, IN, USA). There were seven to eight mice in each group. Mice were monitored twice weekly for tumor growth. Primary tumors were removed and collected by survival surgery 6 weeks after inoculation. Mice were killed 2 weeks after removal of primary tumors to examine metastasis. At the time of killing, the lymph node, lung, liver and bone were collected. All tissues were formalin fixed, and paraffin embedded for histological examination.
Immunohistochemistry
Paraffin-embedded slides were deparaffinized. Antigen was unmasked by incubation in a 95 1C water bath in 10 mM sodium citrate buffer (pH 6.0) for 2 min Â 5 min. Slides were incubated with primary antibody specific to Vimentin (clone SP20, Lab Vision Products) or SV40Tag (Santa Cruz IL-6 promotes prostate tumorigenesis through IGF-IR
